HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Myocardial Infarction

NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Also Known As:
Myocardial Infarct; Infarct, Myocardial; Infarction, Myocardial; Infarctions, Myocardial; Infarcts, Myocardial; Myocardial Infarctions; Myocardial Infarcts
Networked: 59124 relevant articles (3091 outcomes, 10702 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Stroke (Strokes)
2. Heart Failure
3. Unstable Angina
4. Thrombosis (Thrombus)
5. Acute Coronary Syndrome

Experts

1. Stone, Gregg W: 340 articles (01/2016 - 01/2002)
2. Mehran, Roxana: 222 articles (01/2016 - 01/2002)
3. Gibson, C Michael: 176 articles (10/2015 - 01/2002)
4. Braunwald, Eugene: 171 articles (11/2015 - 02/2002)
5. Serruys, Patrick W: 170 articles (12/2015 - 02/2002)
6. Cannon, Christopher P: 157 articles (10/2015 - 07/2002)
7. Murphy, Sabina A: 145 articles (11/2015 - 01/2002)
8. Kastrati, Adnan: 144 articles (12/2015 - 01/2002)
9. Jeong, Myung Ho: 139 articles (12/2015 - 03/2003)
10. Waksman, Ron: 128 articles (12/2015 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myocardial Infarction:
1. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
2. Heparin (Liquaemin)FDA LinkGeneric
3. clopidogrel (Plavix)FDA Link
4. StreptokinaseFDA Link
5. glucuronyl glucosamine glycan sulfate (Vessel)IBA
06/01/2012 - "Excellent target vessel recanalization (Thrombolysis in Myocardial Infarction score of 3) and good outcome at 90 days (modified Rankin Score ≤ 2) were more common in younger patients (45% versus 14%, P = .047, and 41% versus 0%, P = .008, respectively). "
05/01/2009 - "All the treated vessels (100%) were successfully re-canalized, Trials In Myocardial Infarction (TIMI) score of 3. At 90-day follow-up, of the 5 patients treated, 2 had modified Rankin score (mRS) of < 2. This small series shows the safety and efficacy of the Penumbra System in the thrombolysis of large vessel occlusive disease."
05/01/1993 - "Different thrombolytic regimens for acute myocardial infarction proved to be equally effective in large scale mortality trials despite significant differences in their efficacy with respect to early infarct-related vessel patency as shown in smaller angiographic trials. "
12/01/2010 - "In this patient-level pooled analysis, EES compared with PES resulted in a significant and persistent reduction in target vessel failure and major adverse cardiac events at 3 years due to fewer myocardial infarction and ischemic target lesion revascularization events, which is consistent with superior safety and efficacy of the EES platform."
12/01/2009 - "The use of Endeavor versus Driver was associated with a significant reduction in target vessel revascularization through 4-year follow-up with no difference in death, nonfatal myocardial infarction, quality-adjusted survival, or total medical costs. "
6. Glycoproteins (Glycoprotein)IBA
7. Tissue Plasminogen Activator (Alteplase)FDA Link
8. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
9. prasugrelIBA
10. Fibrinolytic Agents (Antithrombotic Agents)IBA

Therapies and Procedures

1. Thrombolytic Therapy
2. Angioplasty (Angioplasty, Transluminal)
3. Stents
4. Transplantation (Transplant Recipients)
5. Coronary Artery Bypass (Coronary Artery Bypass Surgery)